



Grace Freier,* Allen Wright,* Gregory Nelson,*
Eric Brenner,† Sundari Mase,‡ Sybil Tasker,§
Karen L. Matthews,¶ and Bruce K. Bohnker¶
We conducted a tuberculosis contact investigation for
a female military recruit with an unreported history of mul-
tidrug-resistant tuberculosis (MDRTB) and subsequent
recurrence. Pertinent issues included identification of like-
ly contacts from separate training phases, uncertainty on
latent MDRTB infection treatment regimens and side
effects, and subsequent dispersal of the contacts after
exposure.
I
n 2004, a 19-year-old female recruit came to the Naval
Hospital in Beaufort, South Carolina, with a history of
congestion and rhinorrhea for 4 days. Radiographic exam-
ination showed right upper and lower lobe infiltrates. Her
initial recruit screening tuberculin skin test (TST) result
had been reactive. Consultation with her physician in
California indicated similar radiographic findings 2 years
earlier; her condition had been diagnosed as smear- and
culture-negative tuberculosis (TB). She received oral
treatment of 300 mg isoniazid daily, 600 mg rifampin
daily, and 1,500 mg pyrazinamide daily for 2 months.
After a negative sputum culture, isoniazid and rifampin
were continued for 9 months (1,2). Based on unchanged
radiographic findings and 9 months of treatment, her dis-
ease was considered to be nonactive and she returned to
training. Subsequently, she failed to complete training and
was separated from the military.
The Study
Approximately 3 months after her initial treatment, the
index patient was hospitalized in California for TB resist-
ant to isoniazid and rifampin, which met the definition of
multidrug-resistant tuberculosis (MDRTB). Initial isolate
susceptibility in California showed resistance to isoniazid,
rifampin, ethambutol, and streptomycin. Additional isolate
susceptibility tests in Denver showed sensitivity to ethion-
amide, cycloserine, p-amino salicylic acid, clofazimine,
levofloxacin, and pyrazinamide, but resistance to isoni-
azid, rifampin, streptomycin, amikacin/kanamycin, amox-
icillin/clavulanate, and rifabutin.
After notification of the recruit’s hospitalization in
California, Navy personnel began a TB contact investiga-
tion (1). Recruit populations are highly transient, as persons
are frequently added or removed for various medical, den-
tal, legal, or physical performance reasons. Some persons
had multiple exposures to the index patient while in the
training platoon and subsequently in various processing
units. Thus, the contact investigation identified numerous
persons who may have had contact with the index patient;
these were categorized as “close” or “casual” contacts.
Close contacts included persons who shared living quarters
with the index patient; casual contacts included persons
who had less definable contact with the index patient.
The investigation identified 13 close contact and 8
casual contact new reactors, defined as >5 mm TST
indurations in persons who had negative tests previously
(2). These persons were considered likely to have been
infected with the MDRTB strain, though none demonstrat-
ed active disease. Table 1 shows that the close contact
group had a TST reactor proportion of 9.09%. Table 2
shows a 3.1% TST reactor rate for the casual contact group
(risk ratio [RR] 2.86, 95% confidence interval [CI]
1.22–6.74, p = 0.011). The index patient was assigned to
the recruit-training platoon for 3 weeks, a rehabilitation
squad for 9 days, and the separation platoon for 4 days.
The TST reactor proportion for persons with >3 weeks of
exposure in the recruit-training platoon was substantially
lower than shorter duration of exposure in the rehabilita-
tion and separation units (RR 0.19, 95% CI 0.05–0.66, p =
0.0032). A possible explanation for this apparent paradox
would be increasing infectiousness during this later period,
which is supported by progressive clinical symptoms seen
in the index patient.
The optimal treatment protocol for new TST reactors
from likely MDRTB sources is undefined, which leads to
extensive consultation with TB experts to determine treat-
ment timing and medications (3–10). The imminent trans-
fer of reactors to new duty stations and the upcoming
holiday leave period complicated the recommendations.
Timing options included the following: 1) start medication
immediately, retain reactors on base 7–10 days to verify
medication tolerance, and allow self-medication during the
transfer to their next duty station; 2) start medication
immediately, allow self-medication during holiday leave,
and continue therapy at their next duty station; or 3) delay
treatment until reactors complete 2–3 weeks of holiday
leave and initiate treatment at their next duty station.
Ultimately, the graduating recruits were allowed holiday
leave and began therapy at their next duty station.
Because the index patient’s isolate was resistant to iso-
niazid and rifampin, several medication options were
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assessed for medications, adverse effects monitoring (clin-
ical vs. biochemical), duration (4, 6, 9, 12, or 24 months),
and self-administered versus directly observed therapy.
Three options emerged: 1) no medication with close clini-
cal and radiologic monitoring for 2–3 years; 2) monother-
apy with a fluoroquinolone; or 3) two-drug regimen
consisting of pyrazinamide and a fluoroquinolone. This
third option, initially strongly considered from prior rec-
ommendations (4), was not chosen because published case
series suggested poor tolerance and unacceptable hepato-
toxicity (8,9). By consensus, US Navy and Centers for
Disease Control and Prevention (CDC) infectious disease
specialists recommended a fluoroquinolone for at least 12
months. In vitro studies suggest that gatifloxacin and mox-
ifloxacin have greater activity against Mycobacterium
tuberculosis than older fluoroquinolones, though treatment
efficacy for latent TB infection has not been documented
in the literature (11,12). Ultimately, gatifloxacin was
selected based on availability on the Department of
Defense formulary. Therefore, the recruit reactors at high
risk for latent TB infection from the MDRTB isolate were
counseled, and 400 mg gatifloxacin was administered oral-
ly daily. Although the Food and Drug Administration had
not approved gatifloxacin to treat TB, this protocol repre-
sented the most appropriate therapy, based on the limited
data available.
Upon arrival for training, recruits receive a single-step
TST and have historically demonstrated a baseline TST
reactor proportion of 0.35% (13). However, several of the
reactors in the casual exposure category were not recruits
and had vague and limited exposure histories. For exam-
ple, 1 reactor drove a bus that the index patient may have
ridden. Persons in these positions do not routinely undergo
TST screening and would be in populations with unknown
TST conversion rates. Using the “concentric ring
approach,” further investigation on base was deferred
since the conversion proportion of personnel with positive
TST results could not be separated from the background
level in the local population (2). Military personnel would
continue to receive TST surveillance consistent with the
most current Navy medicine policy (1).
Only 6 of the 13 reactors in the higher-risk groups
remained on active duty, and their transfer required explic-
it coordination to ensure appropriate follow-up. In collab-
oration with CDC, military preventive medicine personnel
communicated with 5 state departments of health to ensure
appropriate follow-up for the other 7 TST reactors in the
high-risk group. More than 30 state health departments
were notified of other casual contacts that were dropped
from training.
Conclusions
This contact investigation illustrates the complexities
associated with the public health management of MDRTB
exposures in military recruit training settings. It demon-
strates the importance of close coordination of efforts
among military medical personnel, expert tuberculosis
consultants, CDC, and state health departments in such
cases. It shows some of the uncertainties in the clinical
management of reactors associated with exposure to
MDRTB sources, exacerbated in this case by military
related factors. It highlights the complexities associated
with public health management of MDRTB exposure and
demonstrates the necessity of response preparedness, close
consultation, communication, and coordination of efforts.
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investigations and treatment, although it was generally
handled consistent with that guidance (14,15).
Dr Freier served as a general medical officer at Naval
Hospital Beaufort-Branch Medical Clinic, Parris Island, South
Carolina, when she wrote this article. She is currently completing
her residency in pediatrics at Naval Medical Center, Portsmouth,
Virginia. Dr Freier’s research interests include military recruit
medicine and pediatric infectious disease. 
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